Investing
When Low-Priced Stocks Are The Biggest Leaders (CYBI, MNI, BMTI, SPF)
Published:
Is it a worry when the percentage gainers are all low-priced stocks? For some it may be, others will just say it is the normal process.
Cybex International, Inc. (NASDAQ: CYBI) is up 23% at $1.47 and only on 202,000 shares of volume. This is on the heels the company reaching a settlement in the Barnhard product liability suit.
The McClatchy Company (NYSE: MNI) is up 24% at $2.78 and not quite on 2 million shares as of yet. This surge is after the company beat its earnings predictions and after tuting its digital efforts in the world of old media meets new media.
BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) is up 17% on 2.8 million shares at $2.40. Biomimetic’s news is that the company announced results of its 30 patient Canadian Augment Rotator Cuff Graft clinical trial and that the results achieved the primary safety endpoint.
Standard Pacific Corp. (NYSE: SPF) is up 18.5% to $4.80 on 6.7 million shares. The single-family homebuilder announced earnings ahead of estimates.
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
